In just eight years, the NIH National Institute of Allergy and Infectious Diseases moved from identifying an ultra-rare genetic disorder, CD55 deficiency, hyperactivation of the complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) to FDA approval of its first treatment option

Learn from NIH’s Steve Ferguson during the Licensing Executives Society (LES) Industry, Universities and Government virtual course. Ferguson is a Special Advisor at OTT and brings 30+ years of experience on how to set up successful partnerships with NIH and utilize a variety of available

NIH is issuing an Intramural Research Program (IRP) policy to promote access to IRP-supported inventions resulting in drugs, biologics, vaccines, or devices. As of June 1, 2025, organizations applying to NIH for certain commercial patent licenses will be required to submit Access Plans to NIH